BioCentury | Oct 21, 2020
Finance

Oct. 20 Quick Takes: AbSci raises $65M; plus Aptinyx, Synspira and Aridis

...complications, as well as SNSP003, an enzyme replacement therapy for malabsorption syndromes and exocrine pancreatic insufficiency.Aridis aims...
...the convalescent patient-derived mAb reduced lung and nasal virus levels and signs of lung pathology. BC Staff NYX-783 SNSP003 SNSP113 Aridis Pharmaceuticals Inc. Aptinyx...
BioCentury | Oct 24, 2019
Company News

Management tracks: bluebird's Walsh departing as chief strategy officer; plus JDRF, Akcea, Rigel, Elicio and Progenity

...company Rigel Pharmaceuticals Inc. hired Wolfgang Dummer as CMO. He held the same position at Aridis Pharmaceuticals Inc....
BioCentury | Oct 11, 2019
Company News

Management tracks: Chan leaving FDA’s China office; plus Galera, Aridis and Palladio

...was CFO at Verrica Pharmaceuticals Inc. (NASDAQ:VRCA), where he is succeeded by A. Brian Davis. Aridis Pharmaceuticals Inc....
...Alex Martin for its CEO post. Jonathan Block, Associate Editor U.S. Food and Drug Administration (FDA) Galera Therapeutics Inc. Aridis Pharmaceuticals Inc. Palladio...
BioCentury | Sep 3, 2019
Clinical News

Sept. 3 Clinical Quick Takes: Phase II failure for Aridis, plus Kura, Idorsia, Concert, PegBio

...Aridis discontinuing antibacterial mAb Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) said AR-105 plus standard of care antibiotics missed the primary...
...in a Phase II trial to treat ventilator-associated pneumonia (VAP) caused by Pseudomonas aeruginosa . Aridis...
...AR-301, a mAb against aHL in Phase III for VAP caused by Staphylococcus aureus . Aridis...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...KOSDAQ:086820) 8/20/18 $38.8 $198.0 $222.1 12% Sensyne Health plc (LSE:SENS) 8/14/18 $76.4 $286.8 $258.1 -10% Aridis Pharmaceuticals Inc....
BioCentury | Aug 17, 2018
Financial News

Infectious company Aridis raises $26M in NASDAQ IPO

...Infectious disease mAb company Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) raised $26 million on Aug. 13 through the sale of...
...is at the bottom of the $13-$15 range the company proposed on Aug. 6 (see "Aridis...
...to treat severe hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP) caused by Staphylococcus aureus . Aridis...
BioCentury | Aug 10, 2018
Financial News

Aridis amends IPO

...Immunotherapy company Aridis Pharmaceuticals Inc. (San Jose, Calif.) amended its NASDAQ IPO on Aug. 6 and now plans...
...raise $28 million and be valued at $109.3 million. Aridis' lead compound is salvecin (AR-301). Aridis...
...against Staphylococcus aureus alpha-hemolysin (aHL) generated using MablgX technology. Aridis Pharmaceuticals Inc., San Jose, Calif. Shannon Lehnbeuter Salvecin (AR-301, kbsa301) Aridis Pharmaceuticals Inc. MablgX...
BioCentury | Jul 20, 2018
Financial News

Aridis proposes $34.5M IPO

...Infectious disease company Aridis Pharmaceuticals Inc. (San Jose, Calif.) proposed on July 18 to raise $34.5 million in...
...has completed a Phase IIa trial to treat acute pneumonia caused by S. aureus infection. Aridis...
...in the U.S. and Orphan Drug designation in Europe. Aridis Pharmaceuticals Inc., San Jose, Calif. Brian Moy Salvecin (AR-301, kbsa301) Aridis Pharmaceuticals Inc. S...
BioCentury | Mar 9, 2018
Company News

Aridis, Shenzhen Hepalink form China JV

...of two of Aridis’ candidates, Salvecin (AR-301, kbsa301) and Aerumab panobacumab (AR-101, kbpa101) in China. Aridis...
...significant capital commitment" and that ownership of the JV will be roughly equal. According to Aridis...
...pneumonia (VAP). Aridis said the JV will submit regulatory applications for AR-301 in late 2021. Aridis Pharmaceuticals Inc....
BioCentury | Jan 18, 2016
Clinical News

Aerucin: Phase I data

...ascending doses of <=20 mg/kg IV Aerucin led to no serious adverse events. This year, Aridis...
...an international Phase II trial to treat hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Aridis Pharmaceuticals Inc....
Items per page:
1 - 10 of 19
BioCentury | Oct 21, 2020
Finance

Oct. 20 Quick Takes: AbSci raises $65M; plus Aptinyx, Synspira and Aridis

...complications, as well as SNSP003, an enzyme replacement therapy for malabsorption syndromes and exocrine pancreatic insufficiency.Aridis aims...
...the convalescent patient-derived mAb reduced lung and nasal virus levels and signs of lung pathology. BC Staff NYX-783 SNSP003 SNSP113 Aridis Pharmaceuticals Inc. Aptinyx...
BioCentury | Oct 24, 2019
Company News

Management tracks: bluebird's Walsh departing as chief strategy officer; plus JDRF, Akcea, Rigel, Elicio and Progenity

...company Rigel Pharmaceuticals Inc. hired Wolfgang Dummer as CMO. He held the same position at Aridis Pharmaceuticals Inc....
BioCentury | Oct 11, 2019
Company News

Management tracks: Chan leaving FDA’s China office; plus Galera, Aridis and Palladio

...was CFO at Verrica Pharmaceuticals Inc. (NASDAQ:VRCA), where he is succeeded by A. Brian Davis. Aridis Pharmaceuticals Inc....
...Alex Martin for its CEO post. Jonathan Block, Associate Editor U.S. Food and Drug Administration (FDA) Galera Therapeutics Inc. Aridis Pharmaceuticals Inc. Palladio...
BioCentury | Sep 3, 2019
Clinical News

Sept. 3 Clinical Quick Takes: Phase II failure for Aridis, plus Kura, Idorsia, Concert, PegBio

...Aridis discontinuing antibacterial mAb Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) said AR-105 plus standard of care antibiotics missed the primary...
...in a Phase II trial to treat ventilator-associated pneumonia (VAP) caused by Pseudomonas aeruginosa . Aridis...
...AR-301, a mAb against aHL in Phase III for VAP caused by Staphylococcus aureus . Aridis...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...KOSDAQ:086820) 8/20/18 $38.8 $198.0 $222.1 12% Sensyne Health plc (LSE:SENS) 8/14/18 $76.4 $286.8 $258.1 -10% Aridis Pharmaceuticals Inc....
BioCentury | Aug 17, 2018
Financial News

Infectious company Aridis raises $26M in NASDAQ IPO

...Infectious disease mAb company Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) raised $26 million on Aug. 13 through the sale of...
...is at the bottom of the $13-$15 range the company proposed on Aug. 6 (see "Aridis...
...to treat severe hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP) caused by Staphylococcus aureus . Aridis...
BioCentury | Aug 10, 2018
Financial News

Aridis amends IPO

...Immunotherapy company Aridis Pharmaceuticals Inc. (San Jose, Calif.) amended its NASDAQ IPO on Aug. 6 and now plans...
...raise $28 million and be valued at $109.3 million. Aridis' lead compound is salvecin (AR-301). Aridis...
...against Staphylococcus aureus alpha-hemolysin (aHL) generated using MablgX technology. Aridis Pharmaceuticals Inc., San Jose, Calif. Shannon Lehnbeuter Salvecin (AR-301, kbsa301) Aridis Pharmaceuticals Inc. MablgX...
BioCentury | Jul 20, 2018
Financial News

Aridis proposes $34.5M IPO

...Infectious disease company Aridis Pharmaceuticals Inc. (San Jose, Calif.) proposed on July 18 to raise $34.5 million in...
...has completed a Phase IIa trial to treat acute pneumonia caused by S. aureus infection. Aridis...
...in the U.S. and Orphan Drug designation in Europe. Aridis Pharmaceuticals Inc., San Jose, Calif. Brian Moy Salvecin (AR-301, kbsa301) Aridis Pharmaceuticals Inc. S...
BioCentury | Mar 9, 2018
Company News

Aridis, Shenzhen Hepalink form China JV

...of two of Aridis’ candidates, Salvecin (AR-301, kbsa301) and Aerumab panobacumab (AR-101, kbpa101) in China. Aridis...
...significant capital commitment" and that ownership of the JV will be roughly equal. According to Aridis...
...pneumonia (VAP). Aridis said the JV will submit regulatory applications for AR-301 in late 2021. Aridis Pharmaceuticals Inc....
BioCentury | Jan 18, 2016
Clinical News

Aerucin: Phase I data

...ascending doses of <=20 mg/kg IV Aerucin led to no serious adverse events. This year, Aridis...
...an international Phase II trial to treat hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Aridis Pharmaceuticals Inc....
Items per page:
1 - 10 of 19